These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3830071)

  • 41. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy.
    Antonelli A; Saracino A; Alberti B; Canapicchi R; Cartei F; Lepri A; Laddaga M; Baschieri L
    Acta Endocrinol (Copenh); 1992 Jan; 126(1):13-23. PubMed ID: 1736548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism.
    Manso PG; Furlanetto RP; Wolosker AM; Paiva ER; de Abreu MT; Maciel RM
    Thyroid; 1998 Jan; 8(1):49-52. PubMed ID: 9492153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Orbital radiotherapy for Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Pinchera A
    J Clin Endocrinol Metab; 2004 Jan; 89(1):13-4. PubMed ID: 14715819
    [No Abstract]   [Full Text] [Related]  

  • 44. Enlargement of the tensor intermuscularis muscle in Graves' ophthalmopathy. A computed tomographic and magnetic resonance imaging study.
    Goodall KL; Jackson A; Leatherbarrow B; Whitehouse RW
    Arch Ophthalmol; 1995 Oct; 113(10):1286-9. PubMed ID: 7575261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Supervoltage orbital radiotherapy in 36 cases of Graves' disease.
    Lloyd WC; Leone CR
    Am J Ophthalmol; 1992 Apr; 113(4):374-80. PubMed ID: 1558110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The aftermath of orbital radiotherapy for graves' ophthalmopathy.
    Gorman CA; Garrity JA; Fatourechi V; Bahn RS; Petersen IA; Stafford SL; Earle JD; Forbes GS; Kline RW; Buettner H; Robertson DM; Bergstralh EJ; Offord KP; Rademacher DM; Stanley NM; Bartley GB
    Ophthalmology; 2002 Nov; 109(11):2100-7. PubMed ID: 12414422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiotherapy for moderate-to-severe Graves' ophthalmopathy: improved outcomes with early treatment.
    Alpert TE; Alpert SG; Bersani TA; Hahn SS; Bogart JA; Chung CT
    Cancer J; 2003; 9(6):472-5. PubMed ID: 14740976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclophosphamide in the management of advanced Graves' ophthalmopathy. A preliminary report.
    Bigos ST; Nisula BC; Daniels GH; Eastman RC; Johnston HH; Kohler PO
    Ann Intern Med; 1979 Jun; 90(6):921-3. PubMed ID: 582090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine.
    Barth A; Probst P; Bürgi H
    J Endocrinol Invest; 1991 Mar; 14(3):209-12. PubMed ID: 2071823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. E-rosette formation in Graves' ophthalmopathy.
    Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ
    Invest Ophthalmol Vis Sci; 1979 Dec; 18(12):1245-51. PubMed ID: 92464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of increased intraocular pressure in Graves' disease--evidence of frequent subclinical ophthalmopathy.
    Gamblin GT; Harper DG; Galentine P; Buck DR; Chernow B; Eil C
    N Engl J Med; 1983 Feb; 308(8):420-4. PubMed ID: 6687400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
    Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
    Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves' ophthalmopathy.
    Jankauskiene J; Imbrasiene D
    Medicina (Kaunas); 2006; 42(11):900-3. PubMed ID: 17172791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ocular myasthenia gravis associated with euthyroid ophthalmopathy.
    Kusuhara T; Nakajima M; Imamura A
    Muscle Nerve; 2003 Dec; 28(6):764-6. PubMed ID: 14639594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of Graves' ophthalmopathy and uveitis after radioiodine therapy for Graves' disease in a patient with HTLV-I associated myelopathy (HAM).
    Ozawa Y; Migita M; Watanabe T; Okuda I; Takeshita A; Takagi A; Shishiba Y
    Intern Med; 1994 Sep; 33(9):564-8. PubMed ID: 8000111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic criteria for Graves' ophthalmopathy.
    Bartley GB; Gorman CA
    Am J Ophthalmol; 1995 Jun; 119(6):792-5. PubMed ID: 7785696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radiotherapy of severe ophthalmic Graves' disease.
    van Ouwerkerk BM; Wijngaarde R; Hennemann G; van Andel JG; Krenning EP
    J Endocrinol Invest; 1985 Jun; 8(3):241-7. PubMed ID: 3839805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of response to transantral orbital decompression in severe Graves' ophthalmopathy.
    Fatourechi V; Bergstralh EJ; Garrity JA; Bartley GB; Beatty CW; Offord KP; Gorman CA
    Mayo Clin Proc; 1994 Sep; 69(9):841-8. PubMed ID: 8065185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy.
    Snijders-Keilholz A; De Keizer RJ; Goslings BM; Van Dam EW; Jansen JT; Broerse JJ
    Radiother Oncol; 1996 Jan; 38(1):69-71. PubMed ID: 8850428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.